{
  "docId": "019de074-d961-7389-a20b-cd17e719b042",
  "docSlug": "eb72a4aa6f7d8bed68bc577a406605bf",
  "documentTitle": "BioAtla | Investor Presentation Deck | 44 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 44,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The table lists specific indications (NSCLC, Melanoma, Head and Neck, Ovarian) and their corresponding dosing schedules (Q2W, 3Q4W) and patient counts (N ~ 20 or 40).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d961-7389-a20b-cd17e719b042/34",
  "deckHref": "/decks/019de074-d961-7389-a20b-cd17e719b042",
  "deckJsonHref": "/decks/019de074-d961-7389-a20b-cd17e719b042.json",
  "deckAnchorHref": "/decks/019de074-d961-7389-a20b-cd17e719b042#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.12,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "*Investigator-initiated trial. NSCLC = non small cell lung cancer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "679fb437-ad6f-40b9-a6ac-fad8bf645e68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.78,
        "x": 0.11,
        "y": 0.214
      },
      "kind": "table",
      "text": "Indication, Dose, Patient #. NSCLC, Q2W monotherapy, N ~ 20. NSCLC, Q2W in combo w/ nivolumab, N ~ 20. NSCLC, 3Q4W monotherapy, N ~ 20. Melanoma, Q2W monotherapy, N ~ 20. Melanoma, Q2W in combo w/ nivolumab, N ~ 20. Head and Neck, Q2W monotherapy, N ~ 40. Ovarian*, Q2W in combo w/ durvalumab, N ~ 20.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19cd9e94-a164-4ff6-a7e0-f83bdd8948c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Summary of Dosing Regimens for Phase 2 Clinical Studies with CAB-ROR2-ADC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b88305b8-542c-41e1-b66f-1fa50ff02213",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.28,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "BA3021 Ozuriftamab Vedotin",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08e19f21-695f-4497-9b65-ac017b1c2362",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}